News

Kesimpta: New Study Results Highlight Efficacy in MS Treatment

Kesimpta: New Study Results Highlight Efficacy in MS Treatment

Significant Advancements in Multiple Sclerosis Treatment

Recent data from Novartis reveals compelling insights regarding the effects of Kesimpta® (ofatumumab) as a treatment for relapsing multiple sclerosis (RMS). These findings, to be shared at upcoming scientific meetings, detail significant improvements following the transition from oral disease-modifying therapies (DMTs) to Kesimpta, providing hope for patients facing this debilitating condition.

Promising Results from New Research Studies

The ARTIOS Phase IIIb study demonstrated that patients switching to Kesimpta after experiencing breakthrough disease on fingolimod or fumarate-based therapies exhibited a notable decline in disease activity. With a reported annualized relapse rate (ARR) of just 0.06 over a 96-week period, it’s clear that Kesimpta offers a substantial therapeutic benefit

High Rates of No Evidence of Disease Activity

Remarkably, over 90% of participants who switched to Kesimpta achieved no evidence of disease activity (NEDA-3). This statistic not only underscores the treatment's efficacy but also points to a potential lasting impact on the quality of life for those affected by RMS.

ALITHIOS Study and Long-Term Benefits

In addition to the ARTIOS study, the ALITHIOS open-label extension study highlighted the long-term benefits of Kesimpta. Participants, including those newly diagnosed and treatment-naïve, demonstrated an impressive 90% rate of being progression-free at the seven-year mark. This finding reinforces the necessity of early intervention with Kesimpta to maintain disease stability.

The Importance of Sustained Efficacy

Long-term study results indicated that patients could maintain low ARR and significant MRI activity suppression, signifying that Kesimpta does not just provide temporary relief but can indeed be a part of a long-lasting treatment approach. These results were consistent across diverse patient demographics, with no new safety concerns arising.

Expert Insights on the Findings

Dr. Riley Bove, the lead investigator from the University of California, San Francisco, expressed optimism regarding these results. He stated, “These findings add to the growing evidence on the efficacy and safety of ofatumumab after a switch from oral DMTs. Importantly, we observed robust disease control sustained over two years in patients with RMS who did not respond well to oral DMTs.” This expert support adds substantial weight to the argument for prescribing Kesimpta as an effective treatment for multiple sclerosis.

The Role of Novartis in Neuroscience

For over 80 years, Novartis has been at the forefront of developing innovative treatments for neurological conditions. Their commitment to tackling diseases such as MS has resulted in meaningful advancements that enhance patient care. Through ongoing collaborations and research, Novartis seeks to deliver effective strategies to manage MS and improve the lives of those affected by it.

Understanding Multiple Sclerosis

Multiple sclerosis is characterized by the destruction of myelin, leading to significant neurological damage. With almost 3 million people affected globally, it remains crucial to explore new treatments like Kesimpta that offer hope for managing symptoms and slowing disease progression. Each MS type presents unique challenges, but innovations in treatment can bring patient empowerment and improved outcomes.

About Kesimpta

Kesimpta is a monoclonal antibody that selectively targets B-cells, administered as a subcutaneous injection, allowing for patient convenience and adherence. Its unique design enables effective delivery while preserving essential immune responses. Initially developed by Genmab, Kesimpta is now widely available globally, having treated over 150,000 patients to date.

Frequently Asked Questions

What is Kesimpta?

Kesimpta is a targeted therapy for relapsing forms of multiple sclerosis, designed to manage disease activity effectively.

How does Kesimpta work?

Kesimpta works by depleting B-cells, which are involved in the autoimmune attacks in multiple sclerosis.

What are the main findings of the ARTIOS study?

The ARTIOS study found significant reductions in disease activity among participants who switched to Kesimpta, demonstrating an ARR of 0.06.

How long does Kesimpta take to show results?

Patients in the Studies exhibited improvements within weeks of transitioning, with sustained benefits evident over years.

Where is Kesimpta approved for use?

Kesimpta has been approved in over 92 countries worldwide, reflecting Novartis's global commitment to MS treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading